Development of new or improved anti-cancer treatments are potentially being slowed down by lack of transparency in data sharing between pharmaceutical companies and research groups, a new article claims.
The multidisciplinary team led by Flinders University researchers Mr Natansh Modi and Dr Ashley Hopkins evaluates the literature and policy developments since the 2013 data sharing commitments were struck by US and European regulators, including the commitment to publish clinical trial results.
The agreement forged by the Pharmaceutical Research and Manufacturers of America (PhRMA) and European Federation of Pharmaceutical Industries and Associations (EFPIA) included a commitment to give public access to clinical study reports from clinical trials submitted to the Food and Drug Administration (FDA), European Medicines Agency and EU member states.
However, the new article by researchers, cancer clinicians and consumers published in identifies critical areas for improvement in data sharing and collaboration within the pharmaceutical industry – as well as among all institutions involved in clinical trials.
“It will take even more commitment, time and resources to make a collective effort to enhance the accessibility and transparency of critical data in clinical trials,” says NHMRC , from the Clinical Cancer Epidemiology Lab at the Flinders University College of Medicine and Public Health.
“We have identified a series of evidence-based recommendations to enhance existing principles, promote harmonized data sharing practices, and establish clearer guidelines for pharmaceutical industry data sharing.”
Senior Research Fellow in Pharmacology , adds the Clinical Cancer Epidemiology Lab research is focusing on the “substantial opportunity to enhance the data sharing ecosystem” including ensuring that clinical trials deemed as eligible for sharing be made “truly accessible” and that meet a “standard of utility”.
In a recent study, the Flinders University researchers were allowed access to 70 or 77% of IPDs from 91 trials of FDA-approved carried out in the 12 months to February 9 2023. Access was denied to the remaining 21 trials, and completeness of the data and supporting documentation was variable.
As a result, the BMC Medicine correspondence is calling for updates in sharing and accessibility of participant-level data, clinical study reports, protocols, statistical analysis plans, lay summaries and result publications from pharmaceutical industry-sponsored trials.
Some key recommendations include:
- IMMEDIATE eligibility for sharing participant-level data from any clinical trial underpinning a product label or submitted for drug approval
- PUBLIC availability of full Clinical Study Reports from all clinical trials submitted to support medicine approvals for direct download.
- SHARING protocols and Statistical Analysis Plans for all published clinical trials within six months of enrolling the first participant.
- PROVIDE lay summary documents to all clinical trial participants within 12 months of primary outcome completion, to comply with the European Union Clinical Trials Regulation.
- DISSEMINATION of clinical trial results and result publications not dependent on clinical trial outcome or phase, covering all follow-up data.
- PHARMACEUTICAL companies should have publicly available web pages detailing their data sharing policies, procedures and commitments in a standardised format.
“The proposed policy and process updates should also cover institutions such as universities, medical societies, advocacy groups, regulators, funders and journals involved in reporting and carrying out clinical trials,” Mr Modi says.
“The ultimate goal is to create a data sharing ecosystem that prioritizes science and patient-centred care, benefitting all stakeholders in the field.”
The correspondence, entitled ‘ (2023) by Natansh D Modi, Ganessan Kichenadasse, Tammy C Hoffmann, Mark Haseloff, Jessica M Logan, Areti A Veroniki, Rebecca L Venchiarutti, Amelia K Smit, Haitham Tuffaha, Harindra Jayasekara, Arkady Manning-Bennet, Erin Morton, Ross A McKinnon, Andrew Rowland, Michael MJ Sorich, Ashley M Hopkins has been published in . DOI: 10.1186/s12916-023-03113-0.
Collaborators on the article include researchers from Bond University, University of South Australia, University of Toronto, Flinders Centre for Innovation in Cancer, The University of Sydney, The University of Queensland, The University of Melbourne, Monash University, and other clinical trial organisations.
Acknowledgements: The research was supported by author fellowships or grants from Cancer Council Australia and the ³Ô¹ÏÍøÕ¾ Health and Medical Research Council (NHMRC).
